Hi, Karen
I think my husband was offered the Erbitux because the doctors didn't want to use a neurotoxic drug (which cisplatin is) on a scientist. He also fit the profile the Bonner data indicate that imply an Ertibux advantage, and understands the risk/benefit aspect of the situation. The Bonner data also indicate a correlation between low-moderate EFGR expression and Erbitux efficacy. If Erbitux is a possiblity, ask the doctors if getting EFGR staining on your biopsy samples is possible, or if there are any other biomarkers that would show correlation between Erbitux and a positive result.
The acniform rash that Kelly mentions is positively associated with survival in the Bonner data, especially prominent rash on the first cycle - which happens before the radiation starts. If you go with the Erbitux - and don't get the acniform rash, you could ask about a re-evaluation of the therapy. In the absence of a confirmed biomarker (and several groups are attempting to figure this out) the acniform rash is the best confirmation that I am aware of that it is working. When my husband got his first cycle rash, I kept calling it lovely. Aquaphor helped!
There are several other biological therapies in clinical trial - there is a list on the NCI site - maybe print one or two.
Definately mention the Virginia connection.